title: Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma.
abstract: BACKGROUND
  The synthetic vasoactive intestinal peptide (VIP) analogue Ro 25-1553 is a selective VIP-PACAP type 2 (VPAC(2)) receptor agonist that causes a bronchodilatory effect in guinea pigs in vivo. The effect of Ro 25-1553 given by inhalation to patients with asthma was studied and compared with that of a long acting beta(2) adrenoceptor agonist.
  
  
  METHODS
  Twenty four patients with moderate stable asthma participated in a double blind, randomised, placebo controlled, crossover study. The primary variable was bronchodilatory effect (increase in forced expiratory volume in 1 second, FEV(1)) after inhalation of Ro 25-1553 (100 microg or 600 microg) and formoterol (4.5 microg), respectively. Putative side effects were characterised by monitoring sitting blood pressure, serum potassium, electrocardiography and echocardiography.
  
  
  RESULTS
  Inhalation of 600 microg Ro 25-1553 caused a rapid bronchodilatory effect (geometric mean increase in FEV(1) compared with placebo) within 3 minutes of 6% (95% CI 4 to 9), as did inhalation of formoterol (8% (95% CI 5 to 10)). The corresponding maximum bronchodilatory effect during 24 hours was similar for 600 microg Ro 25-1553 (7% (95% CI 4 to 10)) and the reference bronchodilator formoterol (10% (95% CI 7 to 12)). However, for both doses of Ro 25-1553 the bronchodilatory effect was attenuated 5 hours after inhalation whereas formoterol still had a bronchodilatory effect 12 hours after inhalation. Neither Ro 25-1553 nor formoterol produced any clinically relevant side effects. No drug related difference in adverse events was observed.
  
  
  CONCLUSIONS
  Inhalation of a synthetic selective VPAC(2) receptor agonist constitutes a promising approach for bronchodilation in patients with asthma.
authors.affiliation: Department of Respiratory Medicine and Allergology, Göteborg University, Guldhedsgatan 10A, S-413 46 Göteborg, Sweden. anders.linden@lungall.gu.se
authors.forename: A
authors.initials: A
authors.lastname: Lindén
authors.forename: L
authors.initials: L
authors.lastname: Hansson
authors.forename: A
authors.initials: A
authors.lastname: Andersson
authors.forename: M
authors.initials: M
authors.lastname: Palmqvist
authors.forename: P
authors.initials: P
authors.lastname: Arvidsson
authors.forename: C-G
authors.initials: CG
authors.lastname: Löfdahl
authors.forename: P
authors.initials: P
authors.lastname: Larsson
authors.forename: J
authors.initials: J
authors.lastname: Lötvall
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000008:administration & dosage*; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage* / Q000031:analogs & derivatives*
chemical_list: D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D010456:Peptides, Cyclic; C089777:Ro 25-1553; D014660:Vasoactive Intestinal Peptide